DPP4 and cardiovascular disorder: However, the lack of coordinate reduction in major atherosclerotic events in humans has been disappointing and has lacked a credible mechanistic explanation.[4] While GLP‐1 receptor agonists have been shown to reduce adverse cardiovascular events and cardiovascular mortality,[5] the inhibition of DPP4 in cardiovascular diseases failed to yield a consistent result in human and animal studies.